Thymalfasin therapy accelerates COVID-19 pneumonia rehabilitation through anti-inflammatory mechanisms.

Wang Z, Wang C, Fei X, Wu H, Niu P, Shen C

Pneumonia (Nathan Qld.)25 Sept 2023Cited by 2 (Europe PMC)

PMID37743481PMCIDPMC10518946DOI10.1186/s41479-023-00116-6PepBankPUB-37743481

Summary

IntroductionThymosin drugs are commonly used for the treatment of viral infections due to their immunomodulatory effects. The comprehensive clinical efficacy of Thymalfasin therapy for COVID-19 associated pneumonia is not yet fully researched, another issue, whether the use of thymosin drugs can reduce the rate of COVID-19 progression to severe pneumonia has not been well documented. The aim of the present study was to multi-angle evaluate the clinical efficacy of Thymalfasin therapy for COVID-19 pneumonia by retrospective review of the clinical data of 338 inpatients with common COVID-19 infection who received treatment in our hospital.MethodsThe primary index of observation was whether progression to severe pneumonia occurred within a week after admission, and the secondary indexes were the length of hospital stay, time of negative conversion of COVID-19 antigen, the number of peripheral lymphocytes and white blood cells (WBC), and C-reactive protein (CRP) and procalcitonin (PCT) levels,and the control of pneumonia related symptoms, for example, fever, listlessness, inflammatory exudate area shown on lung CT (%).ResultsThe length of hospital stay of patients in Thymalfasin group was significantly shorter than that of patients in the control group (p < 0.01). The proportion of relief of pneumonia related symptoms (fever, fatigue) in the Thymalfasin therapy group was significantly higher than that in the control group, and the inflammatory exudate area shown on CT was significantly lower than that in the control group (p < 0.05). Multivariate logistic regression analysis showed that the use of Thymalfasin was an independent protective factor affecting the progression to severe pneumonia. Multifactorial Cox model analysis indicated that negative conversion of COVID-19 antigen was significantly faster in patients using Thymalfasin and younger patients.ConclusionThymalfasin therapy has shown excellent clinical efficacy in the treatment of COVID-19 pneumonia, it can reduce inflammatory reactions, promote the relief of COVID-19 pneumonia related symptoms such as fever and fatigue, facilitate effusion absorption, and accelerate COVID-19 pneumonia recovery. Thymalfasin can prevent progression of common COVID-19 infection to severe pneumonia via multiple immunity-enhancing and anti-inflammatory protective mechanisms.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In inpatients with common COVID-19 infection, use of thymalfasin was an independent protective factor against progression to severe pneumonia.
In plain wordsIn hospital patients with COVID-19, thymalfasin use was linked to a lower chance of the illness becoming severe pneumonia.
Peptide
Thymosin alpha-1
Outcome
DecreaseProgression to severe pneumonia within a week
Study
n = 338
Comparator
Control group
Analysis
Primary
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
Multivariate logistic regression analysis showed that the use of Thymalfasin was an independent protective factor affecting the progression to severe pneumonia.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary index of observation was whether progression to severe pneumonia occurred within a week after admission
Summary · context
The aim of the present study was to multi-angle evaluate the clinical efficacy of Thymalfasin therapy for COVID-19 pneumonia by retrospective review of the clinical data of 338 inpatients with common COVID-19 infection who received treatment in our hospital.
Show in the study text Report a problemFND-3774348101
02HumanObservational studyEfficacy outcome
In inpatients with COVID-19, hospital stay was significantly shorter in the thymalfasin group than in the control group.
In plain wordsIn hospital patients with COVID-19, those given thymalfasin were linked to shorter hospital stays than the control group.
Peptide
Thymosin alpha-1
Outcome
DecreaseLength of hospital stay
Study
n = 338
Comparator
Control group
Analysis
Secondary
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
The length of hospital stay of patients in Thymalfasin group was significantly shorter than that of patients in the control group (p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to multi-angle evaluate the clinical efficacy of Thymalfasin therapy for COVID-19 pneumonia by retrospective review of the clinical data of 338 inpatients with common COVID-19 infection who received treatment in our hospital.
Show in the study text Report a problemFND-3774348102
03HumanObservational studyEfficacy outcome
In inpatients with COVID-19, the proportion with relief of fever and fatigue was significantly higher in the thymalfasin group than in the control group.
In plain wordsIn hospital patients with COVID-19, more of those given thymalfasin had fever and tiredness relieved than the control group.
Peptide
Thymosin alpha-1
Outcome
IncreaseRelief of pneumonia related symptoms (fever, fatigue)
Study
n = 338
Comparator
Control group
Analysis
Secondary
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
The proportion of relief of pneumonia related symptoms (fever, fatigue) in the Thymalfasin therapy group was significantly higher than that in the control group, and the inflammatory exudate area shown on CT was significantly lower than that in the control group (p < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to multi-angle evaluate the clinical efficacy of Thymalfasin therapy for COVID-19 pneumonia by retrospective review of the clinical data of 338 inpatients with common COVID-19 infection who received treatment in our hospital.
Show in the study text Report a problemFND-3774348103
04HumanObservational studyEfficacy outcome
In inpatients with COVID-19, the inflammatory exudate area on lung CT was significantly lower in the thymalfasin group than in the control group.
In plain wordsIn hospital patients with COVID-19, those given thymalfasin were linked to a smaller area of lung inflammation on CT than the control group.
Peptide
Thymosin alpha-1
Outcome
DecreaseInflammatory exudate area on lung CT
Study
n = 338
Comparator
Control group
Analysis
Secondary
Outcome group
Inflammation markers · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
The proportion of relief of pneumonia related symptoms (fever, fatigue) in the Thymalfasin therapy group was significantly higher than that in the control group, and the inflammatory exudate area shown on CT was significantly lower than that in the control group (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to multi-angle evaluate the clinical efficacy of Thymalfasin therapy for COVID-19 pneumonia by retrospective review of the clinical data of 338 inpatients with common COVID-19 infection who received treatment in our hospital.
Show in the study text Report a problemFND-3774348104
05HumanObservational studyEfficacy outcome
In inpatients with COVID-19, negative conversion of COVID-19 antigen was significantly faster in patients using thymalfasin.
In plain wordsIn hospital patients with COVID-19, those using thymalfasin were linked to a faster change to a negative antigen test.
Peptide
Thymosin alpha-1
Outcome
DecreaseTime to negative conversion of COVID-19 antigen
Study
n = 338
Analysis
Secondary
Outcome group
Antiviral activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
Multifactorial Cox model analysis indicated that negative conversion of COVID-19 antigen was significantly faster in patients using Thymalfasin and younger patients.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to multi-angle evaluate the clinical efficacy of Thymalfasin therapy for COVID-19 pneumonia by retrospective review of the clinical data of 338 inpatients with common COVID-19 infection who received treatment in our hospital.
Show in the study text Report a problemFND-3774348105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Thymalfasin therapy accelerates COVID-19 pneumonia rehabilitation through anti-inflammatory mechanisms.

Summary

Results from this study5

Version history

Subjects

Publication types

Keywords